News

Steven Adelsheim, MD, discusses what he believes is the need to further recognize that many mental health conditions begin to develop at a young age.

Investigators presented 2 pooled analyses at APA 2019 that explored the safety profile and efficacy of 42mg lumateperone in patients with schizophrenia

A new report from VHA shows synthetic opioids have accounted for a significant count of veteran deaths since 2010.

Investigators presented the results of a 4-week trial examining the efficacy of SEP-363856 at APA 2019 in San Francisco, CA.

This is the first gene therapy approved for a devastating condition that leads to permanent ventilation or death for many patients by age 2.

Lori Raney, MD, of Health Management Associates in Colorado, sat down with us at APA 2019 to discuss how clinicians should address the mental health needs of an aging population.

Investigators presented data from a 2-year, open-label study into the efficacy and safety of lurasidone in children 10 to 17 years old at APA 2019.

Godfrey Pearlson, MD, founding director of the division of psychiatry neuroimaging at Johns Hopkins University, discusses the possibility of using neuroimaging to diagnose psychiatric disorders.

The real-world analysis of epicutaneous therapy for milk-related EoE progressively exposed pediatric patients to their milk allergen.

Lori Raney, MD, psychiatrist and principal with Health Management Associates in CO, discuss what she believes is the most important discussion topic at APA 2019.

Godfrey Pearlson sat down at APA 2019 to discuss his opinion on what the most significant recent advances in neuropsychiatry have been and how they have impacted practice.

Pear Therapeutics and Novartis presented findings from their study exploring the use of digital therapies in addition to traditional treatment in patients with schizophrenia.

Jonathan Avery, MD, addiction psychiatrist and associate professor of psychiatry, sat down with MD Magazine at APA 2019 to discuss his takeaways and caring for patients with co-occurring mental illness and substance use disorder.

An analysis of more than 62,000,000 found that prevalence rates of nonalcoholic fatty liver disease were 3 times higher in patients with Crohn's disease.

Investigators presented information on the 9-month interim results of the ABX464-102 phase 2a examining efficacy in UC patients at DDW 2019.

Ranibizumab was approved for AMD treatment in Korea in 2007, but most supporting trials had been conducted among Caucasian patients.

FDA announced approval of Sorilux Foam, which had previous approval for adults, for adolescents between the ages of 12 and 17.

David Kingdon, MD, FRCPsych, professor of mental health care delivery at the University of Southampton, sat down with MD Magazine at APA 2019 to discuss recent advances in psychosis.

Investigators from Baylor College of Medicine found that dawn to sunset fasting may be a new treatment approach for obesity, metabolic syndrome and NAFLD.

Study from DDW 2019 found that rates of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nonalcoholic cirrhosis was more than double in patients with UC.

A study presented at APA 2019 found that esketamine spray to be an effective, fast-acting treatment for people with treatment-resistant depression.

A study presented at DDW 2019 found that endoscopic retrieval may help prevent further gastric damage from button battery ingestion.

In a study presented at Digestive Disease Week 2019, results indicated the risk of developing Parkinson's disease was 3 times higher in patients who had appendectomies.

FDA approved midazolam nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.

A study presented at DDW 2019 found that women with intrahepatic cholestasis of pregnancy were 5.7 times more likely to have a NAFLD diagnosis

Study presented at DDW 2019 found that walking and resistance training was associated with a lower risk of cirrhosis-related death.

A study presented at DDW 2019 found that endoscopic sleeve gastroplasties found significant and sustainable weight loss among patients 5 years after surgery.

Study presented at DDW 2019 found that transplantation of gut microbes from lean donor could aid weight loss in obese, metabolically healthy recipients.

A review highlights aflibercept’s efficacy in treatment non-responders and points to a couple promising new AMD therapies in development.

The Submitted Biologics Application for AR101, the first potential pediatric food allergy preventive therapy, will be considered on September 13.